Ropes & Gray represented Bain Capital Life Sciences, Bain’s new life sciences fund, in its recent convertible preferred PIPE investment in Dicerna Pharmaceuticals, Inc., a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics. Bain Capital Life Sciences led a syndicate of current and new investors in the stock purchase. Dicerna intends to use the proceeds from the $70 million preferred stock offering to further develop its GalXC™ pipeline programs. The transaction closed on April 12.
The Ropes & Gray team was led by life sciences partner Michael Beauvais and securities & public companies associates Tom Fraser (both of Boston), and included securities & public companies partner Joel Freedman (Boston), life sciences partner Al Cacozza (Washington, D.C.), tax partner Pamela Glazier (New York), securities & public companies associate Ray Grant and life sciences associate Raj Banerjee (both of Boston).
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.